NICE U-turns on Roche's Zelboraf and BMS' Yervoy for advanced malignant melanoma
This article was originally published in Scrip
Executive Summary
In new final draft guidance, NICE, the health technology appraisal institute for England and Wales, has recommended Bristol-Myers Squibb's Yervoy (ipilimumab) and Roche's Zelboraf (vemurafenib) for the treatment of advanced malignant melanoma. Both decisions are based on discounted prices for the drugs as per separately agreed patient access schemes.